MCB Clinical Research Centers | Colorado Springs, CO

Research site

(Unclaimed)

Location

110 S. Parkside Drive, Colorado Springs, Colorado, United States of America

Site insights

Top conditions

Top treatments

Dasotraline

Aticaprant

SPD489

SP-624

SPN-810

BHV-7000

Methylphenidate Hydrochloride

Lisdexamfetamine dimesylate

SPN-812

Pimavanserin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 52 total trials

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling

Major Depressive Disorder

Drug: SP-624

Drug: Placebo

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling

Episodic Migraine

Drug: Placebo-Matching Atogepant

Drug: Atogepant

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

To evaluate long-term safety exposure

Active, not recruiting

Attention Deficit/Hyperactivity Disorder

Drug: Centanafadine Hydrochloride

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) (UBRO PEDS OLE)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients

Active, not recruiting

Attention-Deficit/Hyperactivity Disorder

Drug: SPN-812

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (Ubro Peds)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (GATE-251)

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel....

Enrolling

Major Depressive Disorder

Drug: Zelquistinel